

## AUSTRALIAN PRODUCT INFORMATION

# **Tetanus Immunoglobulin-VF (for Intramuscular Use)** **(Human tetanus immunoglobulin)**

### **1 NAME OF THE MEDICINE**

Human Tetanus Immunoglobulin

### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Tetanus Immunoglobulin-VF is a sterile, preservative-free solution containing 160 mg/mL human plasma proteins and 22.5 mg/mL glycine. At least 98% of the protein is immunoglobulins (mainly IgG), with a tetanus antitoxin activity of not less than 100 IU/mL.

Tetanus Immunoglobulin-VF is manufactured from human plasma collected by Australian Red Cross Lifeblood.

### **3 PHARMACEUTICAL FORM**

Solution for intramuscular injection.

The solution has a pH of 6.6.

### **4 CLINICAL PARTICULARS**

#### **4.1 THERAPEUTIC INDICATIONS**

Tetanus Immunoglobulin-VF is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. It should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last vaccine dose. In all the above instances, active immunisation with a tetanus vaccine should be commenced at the same time (refer to **Table 1**) according to current recommendations. Although Tetanus Immunoglobulin-VF and vaccine can be given at the same time, they should be administered in opposite limbs, using separate syringes.

**Table 1: Guide to tetanus prophylaxis in wound management (refer to Therapeutic indications)**

History of active immunisation	Type of wound			
	Clean, minor wound		All other wounds	
	Tetanus vaccine*	Tetanus Immunoglobulin-VF	Tetanus vaccine*	Tetanus Immunoglobulin-VF
Not immunised or less than 3 doses	Yes	No	Yes	Yes
3 doses or more: <5 years since last dose	No	No	No	No
5 to 10 years since last dose	No	No	Yes	No
>10 years since last dose	Yes	No	Yes	Yes

\* For children less than 8 years old, use of a combined diphtheria/tetanus/pertussis (DTPa) vaccine is recommended in preference to tetanus vaccine alone. For persons 8 years of age or older use a combined diphtheria/tetanus (dT) vaccine in preference to tetanus vaccine alone.

## 4.2 DOSE AND METHOD OF ADMINISTRATION

### Dosage

Good medical care is essential in the prevention of tetanus from fresh wounds. Thorough cleansing and removal of all foreign and necrotic material from the site of injury is important.

The minimum routine prophylactic dose of Tetanus Immunoglobulin-VF (For Intramuscular Use) for adults or children is 250 IU. The dose should be doubled if the wound is grossly contaminated or if more than 24 hours have elapsed between wounding and the seeking of medical attention.

### Administration

If the product appears to be turbid by transmitted light or contains any sediment it must not be used. **The product does not contain an antimicrobial preservative. It must, therefore, be used immediately after opening the vial. Any unused solution must be discarded appropriately.**

Tetanus Immunoglobulin-VF should be brought to room temperature before use, and given slowly by deep intramuscular injection using an appropriate sized needle. If a large dose (more than 5 mL) is required, it is advisable to administer it in divided doses at different sites. Hyaluronidase and/or a suitable local anaesthetic may be added to the injection if desired.

An intravenous preparation of tetanus immunoglobulin (Tetanus Immunoglobulin for intravenous use) is available for patients where large doses are indicated (i.e. treatment of

tetanus), or when the patient has a significant haemostatic defect which may cause bleeding following intramuscular injection.

### 4.3 CONTRAINDICATIONS

Tetanus Immunoglobulin-VF is contraindicated in individuals:

1. With isolated Immunoglobulin A (IgA) deficiency, unless they have been tested and shown not to have circulating anti-IgA antibodies.
2. Who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.

### 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

**Tetanus Immunoglobulin-VF (For Intramuscular Use) MUST NOT be administered intravenously** because of the potential for anaphylactic reactions. Injections must be made intramuscularly, and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel, (Tetanus Immunoglobulin for intravenous use is available when an intravenous product is required).

Tetanus Immunoglobulin-VF should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. In the case of shock, treatment should follow the guidelines of shock therapy.

#### **Pathogen safety**

This product is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically Creutzfeldt-Jakob Disease (CJD) agents, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.

In addition, the manufacturing process for Tetanus Immunoglobulin-VF contains specific steps to reduce the possibility of viral transmission including pasteurisation for viral inactivation and nanofiltration for virus removal. The current procedures applied in the manufacture of this product are effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and the non-enveloped viruses, such as hepatitis A virus (HAV) and human parvovirus B19. Additionally, the product contains specific antibodies directed against human parvovirus B19.

There is no evidence to date that parvovirus B19 can be transmitted by Tetanus Immunoglobulin-VF (IM), which is known to contain antibodies to the virus and the nanofiltration step of the manufacturing process has been shown to remove such viruses (or viruses of similar size).

Immunoglobulins for intramuscular injection, prepared by this process from plasma screened by current methods, have not been implicated in the transmission of viral infectious diseases including human immunodeficiency virus (HIV). Studies using plasma spiked with HIV have shown that the Cohn cold-ethanol fractionation process produces a very large reduction in virus titre with undetectable levels in the immunoglobulin fraction. Epidemiological studies have not recognised any cluster of AIDS patients or HIV seroconversion in immunoglobulin recipients.

Despite these measures, such products may still potentially transmit disease. There is also the possibility that other known or unknown infectious agents may be present in such products.

Vaccination for patients in receipt of medicinal products from human plasma should be considered where appropriate.

### **Use in the elderly**

The use of this product in the elderly population has not been established in appropriate studies. To date, this population is not over-represented in spontaneous reports of adverse events associated with the use of CSL's intramuscular immunoglobulin products.

### **Paediatric use**

The use of this product in the paediatric population has not been established in appropriate studies. To date, this population is not over-represented in spontaneous reports of adverse events associated with the use of CSL's intramuscular immunoglobulin products.

### **Effects on laboratory tests**

After injection of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.

## **4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

Tetanus Immunoglobulin-VF should not be mixed with other pharmaceutical products, except as indicated (see section 4.2 Dose and method of administration).

*Live attenuated virus vaccines:* Passively acquired antibody can interfere with the response to live, attenuated virus vaccines. Therefore, administration of such vaccines, e.g. poliomyelitis or measles, should be deferred until approximately three months after passive immunisation.

*Inactivated vaccines:* Inactivated vaccines may be administered concurrently with passive antibody (although in separate syringes) to induce active immunity as is sometimes done for tetanus-prone wounds.

## **4.6 FERTILITY, PREGNANCY AND LACTATION**

### **Effects on fertility**

No reproductive toxicity studies have been conducted with Tetanus Immunoglobulin-VF (IM). There have been no reports of effects on fertility associated with the use of CSL's plasma-derived therapeutic medicines.

### **Use in pregnancy**

The safety of Tetanus Immunoglobulin-VF (IM) for use in human pregnancy has not been established in controlled clinical trials and therefore it should only be given to pregnant women with caution.

### **Use in lactation**

The safety of Tetanus Immunoglobulin-VF (IM) during lactation has not been established in controlled clinical trials and therefore it should only be given to breast-feeding mothers with caution. Immunoglobulins are excreted in breast milk, however, it is not known whether this applies to passively administered Tetanus Immunoglobulin-VF.

## **4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

No effects on ability to drive and use machines have been observed.

## **4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)**

Local tenderness, erythema and stiffness may occur at the site of injection and may persist for several hours. This may occur after any intramuscular injection. In the clinical trial with Hepatitis B Immunoglobulin, the following general and local reactions were recorded in the 58 healthy subjects (total number of events, up to and including 7 days post injection; pasteurised/unpasteurised product): malaise (20/22 events), drowsiness (13/17 events), induration (10/4 events), sensation of fever (4/4 events), chills (3/3 events), sweating (3/1 events) and warmth/heat when touched (0/4 events). There was an overall higher reporting of local tolerance adverse events at the injection site for the unpasteurised product, such as pain (32/52 events), bruising (10/22 events), redness (2/8 events) and irritation (2/4 events).

Mild pyrexia, malaise, drowsiness and urticaria have been reported occasionally after injections of immunoglobulins. True allergic responses are rare. Skin lesions, headache, dizziness, nausea, generalised hypersensitivity reactions and convulsions have been reported on rare occasions.

## Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

### 4.9 OVERDOSE

The consequences of overdosage are not known.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 PHARMACODYNAMIC PROPERTIES

#### Mechanism of action

Tetanus Immunoglobulin-VF contains high levels of antibodies (mainly IgG) against tetanus toxin. Donations are selected on the basis that they contain high levels of specific antibodies against the toxin of *Clostridium tetani*.

#### Clinical trials

A comparative clinical trial was conducted to investigate the effect of pasteurisation on the *in vivo* behaviour of intramuscular immunoglobulins using Hepatitis B Immunoglobulin (pasteurised and unpasteurised) as the representative of this group of products. Fifty-eight (58) healthy subjects (28 males and 30 females) each received an intramuscular injection of pasteurised (viral inactivated) or unpasteurised Hepatitis B Immunoglobulin. No significant differences were observed.

Twenty-eight (28) subjects received the viral inactivated product. Maximal serum concentration of IgG was reached after  $8.0 \pm 5.5$  days (mean  $\pm$  s.d.), and the estimated half life of IgG was  $27.2 \pm 6.6$  days (mean  $\pm$  s.d.). These values are consistent with ranges observed with other intramuscular immunoglobulin products.

A clinical trial with Tetanus Immunoglobulin-VF has not been conducted.

### 5.2 PHARMACOKINETIC PROPERTIES

Refer to Section 5.1 Pharmacodynamic Properties.

## **5.3 PRECLINICAL SAFETY DATA**

### **Genotoxicity**

No genotoxicity studies have been conducted with Tetanus Immunoglobulin-VF. There have been no reports of such effects associated with the use of CSL's plasma-derived therapeutic medicines.

### **Carcinogenicity**

No carcinogenicity studies have been conducted with Tetanus Immunoglobulin-VF. There have been no reports of such effects associated with the use of CSL's plasma-derived therapeutic medicines.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 LIST OF EXCIPIENTS**

Refer to Section 2 Qualitative and quantitative composition.

### **6.2 INCOMPATIBILITIES**

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

### **6.3 SHELF LIFE**

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

### **6.4 SPECIAL PRECAUTIONS FOR STORAGE**

Store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light. Do not use after the expiry date shown on the label.

### **6.5 NATURE AND CONTENTS OF CONTAINER**

Tetanus Immunoglobulin-VF solution for intramuscular injection is available in single vials containing 250 IU human tetanus antitoxin. The actual volume in the vial is stated on the label.

### **6.6 SPECIAL PRECAUTIONS FOR DISPOSAL**

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

## **6.7 PHYSICOCHEMICAL PROPERTIES**

### **Chemical structure**

Not applicable

### **CAS Number**

None assigned

## **7 MEDICINE SCHEDULE (POISONS STANDARD)**

S4

## **8 SPONSOR**

CSL Behring (Australia) Pty Ltd

ABN 48 160 734 761

189–209 Camp Road

Broadmeadows VIC 3047

Australia

### **Distributed by**

Australian Red Cross Lifeblood

### **For Medical/Technical Enquiries**

TOLL FREE: 1800 642 865

### **For Customer Service Enquiries**

TOLL FREE: 1800 063 892

customerservice@cslbehring.com.au

[www.cslbehring.com.au](http://www.cslbehring.com.au)

## **9 DATE OF FIRST APPROVAL**

07 April 2005

## **10 DATE OF REVISION**

05 May 2020

## SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
<b>All</b>	PI updated to the new format.
<b>4.7</b>	Information added about effects on ability to drive and use machines
<b>2, 8</b>	Name changed to Australian Red Cross Lifeblood